Power3 Medical and University of Thessaly in Greece to Collaborate on Proteomic Discovery of Parkinson's, Alzheimer's and ALS Biomarkers.

HOUSTON -- Power3 Medical Products, Inc. (OTCBB: PWRM), a leading proteomics company specializing in the development and commercialization of early detection diagnostic tests for neurodegenerative diseases and breast cancer, today announced a new major international collaboration with the University of Thessaly in Larissa, Greece, focusing on the proteomic discovery of biomarkers for Parkinson's disease. The collaboration will also extend to cover other neurodegenerative diseases including Alzheimer's disease, and ALS (Amyotrophic Lateral Sclerosis - Lou Gehrig's disease).

The University of Thessaly (www.uth.gr/main/home_en.html) will provide Power3 with clinically confirmed samples of neurodegenerative disease, including age- and gender-match controls. Power3 will use its existing proprietary and patent-pending technologies to analyze the samples, seeking new protein biomarkers for the early detection of neurodegenerative diseases to add to its portfolio.

Steven B. Rash, chairman and CEO of Power3, said he is hopeful that the collaboration will provide more than 300 patient samples, "significantly expanding Power3's already-extensive patient database and further validating the pioneering work we have done in the discovery of blood serum-based biomarkers.

"Power3's collaborative research business model offers distinct and complementary ways for partners such as the University to access our expertise, discoveries and technologies through research agreements and partnerships," he said. "Applying our proprietary technology and methodologies, Power3 has discovered novel protein biomarkers for early detection of Parkinson's, Alzheimer's, ALS, and other neurodegenerative diseases, and has continued to advance the analysis and application of proteomic discovery to elucidate disease mechanisms measurable in blood, identify and stratify disease, and predict patient therapeutic outcomes."

Combining Academia and Professional Research

Mr. Rash called the Power3-University of Thessaly collaboration "an international bridge, from Europe to America, from Greece to Houston, which allows our two organizations to join hands in a mutual effort to diagnose and treat diseases that have a great impact on mankind.

"Working with Dr. Katerina Markopoulou and the Department of Neurology at the University of Thessaly is a unique honor for the Power3 Medical team," Mr. Rash said. "It is an exciting challenge when leaders from academia and professional research merge talents and efforts toward a common good, as we work to discover early, blood-based, non-invasive ways to diagnose Parkinson's and other neurodegenerative diseases," he said.

"It is our hope and belief," Mr. Rash said, "that our biomarkers offer tremendous promise in finding new and powerful diagnostic and therapeutic products in areas with critical unmet needs."

"Our collaboration with Power3," Dr. Markopoulou said, "provides us with a unique opportunity to identify biomarkers that are critically needed to non-invasively diagnose Parkinson's disease and discriminate between Parkinson's and other neurodegenerative diseases."

To date, Power3 has analyzed more than 600 neurodegenerative blood serum samples including samples from Parkinson's patients. Power3 recently announced the discovery of 11 biomarkers which, it said, demonstrated the ability to identify Parkinson's disease in its early stages through blood serum-based testing, as well as differentiate between Parkinson's and Parkinson's-like diseases (see "Power3 Identifies Early-Detection Biomarkers for Parkinson's Disease; Can Differentiate between Parkinson's and Parkinson's-like Diseases at Early Stages," Business Wire, September 6, 2006).

About Power3 Medical Products

Power3 Medical Products, Inc. (PWRM.PK, www.Power3Medical.com), is a leading proteomics company engaged in the commercialization of protein biomarkers, pathways, and mechanisms of diseases, through the development of diagnostic tests and drug targets for cancer and neurodegenerative diseases. Power3's patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and treatment of disease, and its identified protein biomarkers, drug targets, and diagnostic tests are targeted toward markets with critical unmet needs in areas such as breast cancer and neurodegenerative disease. Power3 operates a state-of-the-art proteomics laboratory in The Woodlands (Houston), Texas.

This press release contains forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement.